GlassScriptPhysician profile
Maria A Stumo
NPI 1326065350
$2,900.98
in general payments reported to CMS, 2019-2025
31 companies · $667 in 2025
The $667 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $363 · 2022: $596 · 2023: $524 · 2024: $752 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $738.53 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $340.72 | 2021-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $203.66 | 2021-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $172.85 | 2021-2025 | Farxiga |
| Pfizer INC. | $151.36 | 2022-2025 | |
| Amgen INC. | $133.16 | 2022-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.07 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $96.61 | 2024-2025 | Eliquis, Camzyos |
| Inspire Medical Systems, INC. | $85.64 | 2024 | Inspire |
| Amarin Pharma, INC. | $71.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $67.58 | 2021-2025 | Verquvo |
| Abbott Laboratories | $64.20 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Daiichi Sankyo INC. | $62.08 | 2024 | Injectafer |
| Novo Nordisk INC | $59.32 | 2022-2024 | Wegovy |
| Boston Scientific Corporation | $54.77 | 2022-2023 | Watchman Access System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $48.18 | 2022-2023 | Uptravi, Opsumit |
| Genzyme Corporation | $38.67 | 2025 | |
| Cvrx, INC. | $38.60 | 2022 | |
| Csl Behring | $37.14 | 2023 | Kcentra |
| Medtronic, INC. | $37.02 | 2021-2022 | |
| United Therapeutics Corporation | $36.49 | 2025 | Tyvaso |
| Edwards Lifesciences Corporation | $34.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.37 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $30.30 | 2021-2022 | |
| Chiesi USA, INC. | $27.66 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $27.66 | 2024 | |
| Astellas Pharma US INC | $27.52 | 2021-2022 | |
| Bridgebio Pharma, INC. | $20.51 | 2025 | Attruby |
| Abiomed | $18.94 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.68 | 2025 | Lifevest |
| G Medical Diagnostic Services, INC. | $13.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Stumo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.